IMMUNOVANT INC IMVT 深 沪
已收盘 12-19 16:00:00 美东时间
26.65
+0.470
+1.80%
华盛通- 最 高27.69
- 今 开26.44
- 成交量 164.33万股
- 最 低 21.93
- 昨 收 26.18
- 总市值 31.18亿
- 52周最高 27.69
- 市盈率 静 --
- 换手率 1.40%
- 52周最低 12.72
- 委 比 -7.07%
- 总股本 1.17亿
- 历史最高 53.75
- 量 比 0.67
- 振 幅 22.00%
- 历史最低 1.10
- 每 手 1
- 风险率 3.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Roivant Signals Major Pipeline Momentum With Accelerated Timelines
Roivant (NASDAQ: ROIV) outlined accelerated timelines and expanded commercial ambitions for several late-stage programs.
12-12 02:39
Immunovant Q2 EPS $(0.73) Misses $(0.72) Estimate
Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.72) by 0.69 percent. This is a 1.35 percent increase over losses of $(0.74) per share from the
11-10 20:03
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
11-10 19:12
Insights into Immunovant's Upcoming Earnings
Immunovant (NASDAQ:IMVT) will release its quarterly earnings report on Monday, ...
11-07 22:02
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025
Immunovant's new management team is advancing IMVT-1402 for six indications, including potentially registrational studies in Graves’ disease and Sjögren’s disease. Positive data from batoclimab trials in MG and CIDP show deeper IgG reductions linked to better outcomes, suggesting IMVT-1402's best-in-class potential. The company has a strong cash position to support ongoing programs through 2027.
05-29 11:00
Guggenheim Reiterates Buy on Immunovantto Buy
Guggenheim analyst Yatin Suneja reiterates Immunovant (NASDAQ:IMVT) from Buy to Buy.
03-11 00:18
2025年美股Biotech有望大涨 摩根大通首选福泰制药
华尔街金融巨头摩根大通近日发布研报称，对于2025年美股市场的生物科技公司（即Biotech）股价走势持乐观看涨立场，预计Biotech有望跑赢美股大盘，其中美股Biotech领军者之一的福泰制药（VRTX.US）在摩根大通的2025年最佳Biotech选股名单中位列榜首。在美联储开启降息的大背景下，生物科技类股票可谓是最佳受益于降息周期的股票板块，在降息周期之下资金有望从近年来股价持续暴涨且估值处于历史高位的大型科技巨头们转向一些受益于降息周期且估值自2022年以来长期低迷的生物科技股。 据了解，在摩根大通最新发布的研报中，该机构2025年最看好的生物科技公司除了位列股票名单首选位置...
2024-11-26 15:22
Cantor Fitzgerald Reiterates Overweight on Immunovant
Cantor Fitzgerald analyst Louise Chen reiterates Immunovant (NASDAQ:IMVT) with a Overweight.
2024-09-10 01:06
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?
Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves' Disease, showing a high response rate and significant IgG reduction. A pivotal trial is expected to start by the end of 2024.
2024-09-10 00:54
Top 2 Health Care Stocks That May Collapse This Quarter
As of Sept. 9, 2024, two stocks in the health care sector could be flashing a r...
2024-09-09 21:12
